|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||88.22 - 90.39|
|52 Week Range||46.51 - 103.70|
|PE Ratio (TTM)||45.61|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.
The Zacks Analyst Blog Highlights: KEMET, Heska, Spirit AeroSystems, American Woodmark and Kraton
Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.